Pemetrexed

Generic Name: Pemetrexed

Brand Names: Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₁N_₅O_₆

CAS Number: 137281-23-3

Unique Ingredient Identifier: 04Q9AIZ7NO

Background: Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.

Indication: Pemetrexed is indicated for the treatment of the following conditions:

Non-squamous non-small cell lung cancer (NSCLC)

Malignant pleural mesothelioma

Associated Conditions: Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma

Associated Therapies: Monotherapy

Clinical Trials

Strategies for Maintenance Therapies in Advanced Non Small Cell Lung Cancer

Phase 3

Completed

Conditions: Advanced Non Small Cell Lung Cancer

Interventions: Drug: Cisplatin
Drug: Pemetrexed
Drug: Gemcitabine

First Posted Date: 2012-06-28

Last Posted Date: 2018-01-17

Lead Sponsor: Intergroupe Francophone de Cancerologie Thoracique

Target Recruit Count: 932

Registration Number: NCT01631136

Locations: 🇫🇷
CHU, Poitiers, France
🇫🇷
CHU Besancon - Pneumologie, Besancon, France
🇫🇷
Castelnau Le Lez - Clinique, Castelnau, France

and more 86 locations

Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases

Phase 2

Completed

Conditions: Lung Adenocarcinoma
Brain Metastases

Interventions: Drug: erlotinib
Drug: pemetrexed
Drug: cisplatin

First Posted Date: 2012-04-17

Last Posted Date: 2015-01-26

Lead Sponsor: Guangzhou Medical University

Target Recruit Count: 69

Registration Number: NCT01578668

Locations: 🇨🇳
The first affiliated hospital of Guangzhou MC, Guangzhou, Guangdong, China

A Phase II Trial to Assess TroVax® Plus Chemotherapy in Patients With Malignant Pleural Mesothelioma

Phase 2

Conditions: Pleural
Malignant
Mesothelioma

Interventions: Biological: TroVax®
Drug: Pemetrexed
Drug: Cisplatin
Dietary Supplement: Vitamin B12
Dietary Supplement: Folic Acid
Drug: Dexamethasone

First Posted Date: 2012-04-03

Last Posted Date: 2013-03-12

Lead Sponsor: Wales Cancer Trials Unit

Target Recruit Count: 26

Registration Number: NCT01569919

Locations: 🇬🇧
Velindre Cancer Centre, Cardiff, South Wales, United Kingdom

Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Erlotinib
Drug: Pemetrexed

First Posted Date: 2012-03-28

Last Posted Date: 2014-09-15

Lead Sponsor: Si-Yu Wang

Target Recruit Count: 123

Registration Number: NCT01565538

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Afatinib With CT and RT for EGFR-Mutant NSCLC

Phase 2

Active, not recruiting

Conditions: Lung Cancer

Interventions: Drug: Afatinib
Radiation: Radiation
Drug: Cisplatin
Drug: Pemetrexed
Procedure: Surgery

First Posted Date: 2012-03-14

Last Posted Date: 2024-11-20

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 19

Registration Number: NCT01553942

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States